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Salicylsalicylic Acid Causes Less 
Gastroduodenal Mucosal Damage than 
Enteric-Coated Aspirin 
An Endoscopic Comparison 
JAMES M. SCHEIMAN, MD, ELIZABETH M. BEHLER, ROSEMARY R. BERARDI, PHARM D, 
and GRACE H. ELTA, MD 
The gastroduodenal mucosal damage caused by aspirin and nonsteroidal antffnflamma- 
tory drugs is a common clinical problem. We compared two medications designed to 
diminish mucosal damage: enteric-coated aspirin and salicylsalicylic acid (salsalate). Ten 
healthy volunteers were randomized to receive either 1.5 g salsalate twice a day or 650 mg 
enteric-coated aspirin four times a day for  six days and were then crossed over to the other 
drug after a one-week medication-free period. Endoscopic inspection o f  gastroduodenal 
mucosa was performed at entry and again after six days o f  drug therapy for each 
medicine. Mean serum salicylate concentrations taken before the morning drug dose were 
11.2 mg/dl for enteric-coated aspirin and 18.1 mg/dl for salsalate. Only one o f  lO subjects 
receiving salsalate developed mild (grade 1) mucosal damage while six o f  10 receiving 
enteric-coated aspirin developed moderate to severe damage (grade 2-3) (P = 0.01). 
Symptoms were mild in both groups. We conclude that salsalate causes less gastroduo- 
denal mucosal damage than enteric-coated aspirin. 
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Salicylates are among the most widely used drugs in 
clinical practice. Aspirin remains the cornerstone of 
therapy for rheumatoid arthritis and other mus- 
culoskeletal disorders. The damaging effect of aspi- 
rin and nonsteroidal anti-inflammatory drugs on 
gastroduodenal mucosa is well known. Quantitation 
of aspirin-related mucosal damage can be assessed 
by endoscopic evaluation as well as by measure- 
ment of fecal blood loss. Both techniques have 
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demonstrated a dose-response relationship be- 
tween aspirin dose, mucosal damage, and ulti- 
mately the risk of chronic gastric ulcer (1). Buffered 
and enteric-coated aspirin preparations have been 
developed in an attempt to lessen gastroduodenal 
mucosal damage. Two studies have concluded that 
enteric-coated aspirin causes considerably less mu- 
cosal damage than either plain or buffered aspirin 
(2, 3). 
Salicylsalicylic acid (salsalate), a salicylate ester 
of salicylic acid, was originally developed as a safer 
nonacetylated alternative to aspirin (4). All salicy- 
lates are hydrolyzed to salicylic acid. Unlike ace- 
tylsalicylate, salsalate yields two molecules of 
salicylic acid. Since the drug is insoluble in acidic 
gastric fluids, it is a stomach-bypassing salicylate as 
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TABLE 1. ENDOSCOPY RATING SCALE 
Grade Description 
0 Normal 
1 Less than 3 areas of mucosal hemorrhage or erosions 
2 3-10 areas of mucosal hemorrhage or erosion 
3 Widespread involvement or greater than 10 areas of 
erosions with active bleeding 
is enter ic-coated aspirin. Salsalate has been  studied 
by both measurements  of  fecal blood loss (5-7) and 
the gas t rocamera  (8), an early endoscopic instru- 
ment ,  and repor tedly  shows little or no evidence of 
gastric mucosal  damage.  We have per formed a 
randomized,  single-blind endoscopic  study of the 
gastroduodenal  effects of  enter ic-coated aspirin and 
salsalate, two preparat ions  designed to spare mu- 
cosa.  This compar ison  may help to guide therapeu- 
tic choices be tween  salicylate preparat ions.  
MATERIALS AND METHODS 
Ten healthy volunteers between the ages of 18 and 35 
(seven males, three females) with no history of gastroin- 
testinal disease, alcohol abuse, or regular aspirin or 
nonsteroidal antiinflammatory drug use were randomized 
to receive either salsalate 1.5 g (2 x 750 mg tablets) orally 
twice a day or enteric-coated aspirin 650 mg (2 x 325 mg 
tables) orally four times a day for six days. Subjects were 
instructed to avoid all other medicines and alcohol 
throughout the study. The doses administered are stan- 
dard recommended doses in clinical practice. An initial 
endoscopy was performed prior to drug administration to 
assess mucosal integrity. A symptom diary was provided 
to record any occurrence of side effects in the subjects. 
After six days of drug administration, the AM medication 
was omitted on the Seventh day and a serum salicylate 
concentration was drawn reflecting blood concentrations 
approximately 10 hr after the preceding dose of medicine. 
Serum salicylate measurements were obtained by the 
Dupont automated clinical analyzer using the Natelson 
colorimetric technique. Endoscopies were performed by 
the same endoscopist blinded to the drug that the volun- 
teer had been taking. The endosopic findings were graded 
using a modification of the gastroscopy rating scale of 
Lanza et al (2) (Table 1). Medication compliance was 
confirmed by return of dispensed medication for pill 
counts. 
After a seven-day washout period, the subjects under- 
went an additional endoscopy to confirm resolution of 
any previous drug-induced changes and then were 
crossed over to the other medication. On the seventh day, 
a serum salicylate level was obtained and endoscopy was 
again performed. 
Statistical analysis of endoscopy scores obtained after 
drug treatment was performed with the Wilcoxon signed 
rank test. 
Informed written consent was obtained from all volun- 
teers before participation. The sudy was approved by the 
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University of Michigan Human Use Committee, Ann 
Arbor, Michigan. 
RESULTS 
Endoscopic Findings. Only one volunteer  (subject 
10) had endoscopic  evidence of  mucosal  damage on 
the initial endoscopy,  two 6-mm antral erosions,  
prior to drug administration. Two  subjects had 
minimal duodenal  e ry thema  on control  endoscopy 
with no change in endoscopic  appearance  with drug 
administration. Two  additional subjects had prepy-  
loric areas of  e ry thema  (<5 m m  each),  which 
resolved during drug administration.  AU volunteers 
had return to baseline endoscopic  appearance  after 
the one-week medicat ion-free washout  period. 
After salsalate administration,  only one of  the 10 
subjects developed any  evidence  of  mucosal  dam- 
age, which was only grade 1 severi ty (Table 2). This 
one subject received the salsalate in the first treat- 
ment  period. Six of  10 subjects taking enteric- 
coated aspirin developed gast roduodenal  lesions: 
one with grade 2 damage and five with grade 3 
lesions. Three  of  these six subjects were  random- 
ized to receive the enter ic-coated aspirin in the first 
t reatment  period and three received it in the second 
t reatment  period. Using the Wilcoxon signed rank 
test, the difference in mucosal  damage  in enteric- 
coated aspirin vs salsalate was statistically signifi- 
cant with P = 0.01. One of  the five subjects with 
grade 3 lesions developed a duodenal  ulcer while 
receiving enter ic-coated aspirin (subject 10); ex- 
cluding this normal  volunteer  due to his baseline 
antral endoscopic  abnormal i ty  does not alter the 
statistical significance of  the difference in endo- 
TABLE 2. ENDOSCOPY SCORES AND SERUM SALICYLATE LEVELS 
IN 10 VOLUNTEERS ON SALSALATE AND 
ENTERIC-COATED ASPIRIN 
Salsalate Enteric-coated aspirin 
Endoscopy Salicylate Endoscopy Salicylate 
Subject score level (mg/dl) score level (mg/dl) 
1 0 38.8 0 10.0 
2 0 19.0 3 15.6 
3 0 10.0 2 6.6 
4 0 24.7 0 5.6 
5 0 16.5 0 8.9 
6 0 17.0 3 9.6 
7 1 16.3 0 12.2 
8 0 18.0 3 15.4 
9 0 6.9 3 14.1 
10" 0 13.4 3 13.8 
*Volunteer 10 had a score of 1 on each baseline endoscopy. All 
other baseline scores were 0. 
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ENDOSCOPIC COMPARISON OF SALICYLATES 
scopy scores (P = 0.02). The distribution of muco- 
sal damage in the seven volunteers who developed 
lesions always involved the stomach but also in- 
cluded duodenum in three of the six subjects on 
Ecotrin (including subject 10 who developed a duo- 
denal ulcer). 
Symptoms. All symptoms were graded in severity 
from 0 to 5. Tinnitus was the only troublesome side 
effect of moderate severity in three of 10 subjects on 
salsalate. One other volunteer on salsalate had mild 
tinnitus. All other side effects were mild and did not 
occur daily but included nausea or heartburn in two 
volunteers on salsalate. Five of 10 subjects receiv- 
ing enteric-coated aspirin developed mild side ef- 
fects, including two with tinnitus, and one each with 
abdominal pain, heartburn, nausea, and minor 
epistaxis. The incidence of tinnitus was not associ- 
ated with the serum salicylate values obtained. 
Salieylate Levels. Mean fasting salicylate concen- 
trations after six days of drug administration drawn 
approximately 10 hr after the preceding dose were 
18.1 mg/dl for salsalate and 11.2 mg/dl for enteric- 
coated aspirin (Table 2). There was no association 
between salicylate levels and gastroduodenal dam- 
age. 
DISCUSSION 
The mechanism of aspirin-induced gastrointesti- 
nal mucosal damage appears, at least in part, to be 
interference with endogenous prostaglandin pro- 
duction with subsequent impairment of mucosal 
defense. Gastric acidity plays an important role in 
the mucosal damage once the normal barrier to 
mucosal H + ion back-diffusion is altered. Much of 
aspirin's effect on mucosal defense may be caused 
by the acetyl group, which acetylates and inhibits 
prostaglandin synthetase (9). The nonacetylated 
salicylates, such as salsalate, are very weak inhib- 
itors of prostaglandin synthesis in vivo (10), yet are 
reportedly effective in rheumatologic diseases. This 
may be due to the effect of salicylates on other 
mediators of inflammation (11). Similarly, the lack 
of effect of nonacetylated salicylates on platelet 
function (12) is consistent with an absence of  in vivo 
prostaglandin interference. Therefore, the gastroin- 
testinal sparing effect of salsalate may be due, at 
least in part, to its lack of acetylation. In addition, a 
recent study (13) has suggested that salicylates alter 
acid secretion, which may also be important in the 
pathogenesis of aspirin-induced gastric damage. Pa- 
renteral salicylic acid inhibits acid secretion to a 
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much greater extent than acetylsalicylic acid. This 
correlates with a lack of gastric damage with the 
nonacetylated agent. When luminal pH was low- 
ered by acid instillation in a rat model of salicylate 
damage, both salicylic acid and acetylsalicylic acid 
caused equivalent damage (13). 
Another possible mechanism for the mucosal 
sparing effect of salsalate is its lack of gastric 
absorption. Salsalate is practically insoluble in the 
acid pH of the stomach but is freely soluble at 
neutral intestinal pH. In contrast aspirin, in its 
nonionized form, can be passively absorbed in the 
stomach. Enteric-coated preparations, which are 
insoluble in acid but soluble at neutral intestinal pH, 
reportedly cause less gastric mucosal damage than 
plain aspirin due to bypassing gastric absorption. 
Endoscopic evidence of damage with enteric- 
coated aspirin still occurs but is less than that of 
plain aspirin in normal volunteers (2, 3). In rheu- 
matic patients, enteric coating also leads to a lower 
frequency of gastric damage (14) but apparently not 
duodenal damage (15). 
We performed an endoscopic comparison of two 
salicylate preparations both of which bypass gastric 
absorption. Our endoscopic observations demon- 
strate less gastroduodenal damage with salsalate 
than with enteric-coated aspirin in the doses admin- 
istered. Only one subject developed mild mucosal 
damage on salsalate while six of 10 subjects taking 
enteric-coated aspirin had multiple mucosal lesions. 
The additional mucosal sparing effect of salsalate 
may be due to its nonacetylation, which differen- 
tially affects two processes: (1) prostaglandin syn- 
thesis and (2) acid secretion. Our endoscopic results 
are consistent with previous studies showing little 
fecal blood loss on salsalate therapy (5, 6). 
The doses chosen for this study are standard 
doses used in clinical practice. It has been demon- 
strated that the average doses required to maintain 
plasma salicylate concentrations in antiinflamma- 
tory therapeutic range would be 5 g daily of aspirin 
versus 3.6 g daily of salsalate (16). Therefore, our 
study was actually biased against salsalate since our 
aspirin dose, 2.6 g daily, versus salsalate, 3.0 g 
daily, may have resulted in less than equivalent 
salicylate concentrations. The higher serum salicy- 
late concentrations obtained with salsalate may 
reflect the doses used, the 10-hr time interval from 
previous dose to blood sampling, or altered disso- 
lution and absorption of the enteric-coated form. 
The frequent side effect of tinnitus on salsalate 
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wou ld  again suggest  that ,  if anyth ing ,  our  dos ing  
r eg imen  was  b iased  agains t  salsalate.  
In  conc lus ion ,  our  s tudy  shows that  salsalate 
causes  less endoscop ic  ev idence  of  mucosa l  dam- 
age t han  en te r i c -coa ted  aspi r in  after six days of  
admin i s t r a t i on  in hea l thy  vo lun tee r s .  Longe r - t e r m  
studies  in rheuma t i c  pa t i en t s  need  to be pe r fo rmed  
to conf i rm these  p romis ing  resul ts .  
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